MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-10-31, ANIX had -$27K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$27K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-10-31
Net loss
-11,028
Stock option compensation to employees and directors
3,681
Stock options issued to consultants
129
Amortization of operating lease right-of-use asset
36
Amortization of discount on held-to-maturity securities
143
Receivables
-173
Prepaid expenses and other current assets
-552
Accounts payable
-360
Accrued expenses
-185
Operating lease liability
-28
Net cash used in operating activities
-7,173
Disbursements to acquire short-term investments
44,360
Proceeds from maturities of short-term investments
49,226
Net cash provided by investing activities
4,866
Proceeds from sale of common stock in an at-the-market offering, net of offering expenses of 183 and 168, for the years ended october 31, 2025 and 2024, respectively
2,378
Proceeds from sale of common stock pursuant to employee stock purchase plan
7
Net (costs) proceeds from exercise of stock options
-105
Net cash provided by financing activities
2,280
Net (decrease) increase in cash and cash equivalents
-27
Cash and cash equivalents at beginning of period
1,271
Cash and cash equivalents at end of period
1,244
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Anixa Biosciences Inc (ANIX)

Anixa Biosciences Inc (ANIX)